CD8A and neoplasm: Among them, DC vaccines may elicit and improve antitumor T cell immunity.35 36 Wculek et al found that dead tumor antigen activates DCs ex vivo, and on adoptive transfer in vivo, these DCs induce strong CD8+ T cell responses through antigen cross-presentation and halt the progression of engrafted cancer models.